Welcome to our dedicated page for Ib Acquisition SEC filings (Ticker: IBAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IB Acquisition Corp. filings document the formal disclosure record of a SPAC, including trust-account amendments, deadline-extension mechanics, shareholder votes, material definitive agreements and capital-structure terms. The company’s reports describe common stock and rights listed on Nasdaq, with each right entitling the holder to receive one-twentieth of one share upon consummation of an initial business combination.
Its SEC record includes Form 8-K material-event reports and proxy materials covering special-meeting proposals, amendments to the Investment Management Trust Agreement, articles-of-incorporation changes, redemption and liquidation provisions, governance matters and business-combination related agreements.
IB Acquisition Corp. reported a net loss of $639,866 for the quarter ended March 31, 2026, driven by higher general and administrative expenses of $748,177 and reduced interest income from its trust investments.
The SPAC’s trust account balance fell to $8.19M after significant redemptions, including about $7.9M at roughly $10.78 per share in March 2026. Common stock subject to possible redemption declined to 759,139 shares, while 4,249,090 non‑redeemable shares remained outstanding.
IB Acquisition entered into a Business Combination Agreement with GNQ Insilico Inc. and arranged up to $2.0M of 10% secured convertible bridge financing to support GNQ ahead of closing. Management disclosed only $4,634 of cash outside the trust and a working capital deficit of $1.55M, concluding these conditions raise substantial doubt about the company’s ability to continue as a going concern absent a successful merger.
IB Acquisition Corp. filed an 8-K reporting that GNQ Insilico, Inc. entered a global Joint Initiative Marketing Agreement with IBM, signed in March 2026, to accelerate adoption of personalized, data-driven medicine. The press release is attached as Exhibit 99.1.
This report also states that the filing relates to a proposed business combination between IBAC and GNQ. IBAC intends to file a registration statement on Form S-4 that will include a proxy statement/prospectus to be sent to IBAC stockholders. The 8-K cautions that the transaction remains subject to customary closing conditions and regulatory approvals.
IB Acquisition Corp. schedule amendment shows AQR Capital Management, LLC, AQR Capital Management Holdings, LLC and AQR Arbitrage, LLC report 0 shares beneficially owned of common stock, representing 0% of the class as of 03/31/2026. The filing lists issuer address and identifies parent/subsidiary relationships; it is signed and dated 04/08/2026.
IB Acquisition Corp. obtained stockholder approval to extend the deadline to complete its initial business combination from March 28, 2026 to September 28, 2026 through amendments to its trust agreement and articles of incorporation. If no deal is completed by September 28, 2026, the trust account will be liquidated under specified redemption and liquidation procedures, with no trust amounts used to pay dissolution expenses. The changes also clarify that trust funds generally remain locked except for interest used to pay franchise and income taxes, and reinforce public stockholders’ rights to redeem their shares in connection with key charter amendments affecting redemptions or the business combination timeline.
IB Acquisition Corp. reported the results of a special stockholder meeting and related redemptions of its common stock. Stockholders owning 5,077,821 shares, or about 88.46% of shares outstanding as of the February 11, 2026 record date, were present or represented by proxy.
Each proposal voted on at the meeting received 5,007,821 votes for and 70,000 against, with no abstentions or broker non-votes, so all proposals were approved. Separately, holders of 731,741 shares chose to redeem their shares for cash at approximately $10.78 per share from the company’s trust account.
These redemptions will remove about $7.9 million from the trust account, leaving approximately $8.2 million remaining. The remaining trust balance may change to reflect tax withdrawals.
AQR-affiliated investment funds reported open-market sales of IB Acquisition Corp. common stock. On March 23, 2026, entities managed by AQR Capital Management sold a combined 335,000 shares of common stock at $10.80 per share.
The transactions were executed across multiple vehicles, including AQR Global Alternative Investment Offshore Fund, L.P., which held 143,785 shares after its sale, and other funds such as AQR Diversified Arbitrage Fund and several AQR arbitrage and UCITS funds. The sales are reported by AQR Capital Management Holdings, LLC, AQR Capital Management, LLC, and AQR Arbitrage LLC as indirect holdings of ten percent owners.
AQR-related investment entities reported an open-market sale of IB Acquisition Corp. common stock. An account identified as AQR DELTA Master Account, L.P. sold 4,619 shares of common stock on 2026-03-20 at $10.75 per share in an indirect transaction. After this sale, that indirect account held 0 shares of IB Acquisition Corp.
IB Acquisition Corp. reported that GNQ Insilico Inc. entered a Joint Initiative Agreement and Joint Marketing Attachment with a Fortune 100 global technology company on March 13, 2026 to collaborate on sales, marketing, development and alliance activities advancing AI-driven drug discovery and precision medicine solutions.
The collaboration has a global territory, an initial term of two years and is non-exclusive. The parties will jointly market combined solutions that integrate GNQ’s AI platforms with the Strategic Partner’s consulting, cloud, and quantum computing capabilities. This Form 8-K also states that IB Acquisition intends to file a Form S-4 registration statement and a proxy statement/prospectus in connection with the proposed business combination with GNQ.
IB Acquisition Corp. reports that its prospective merger partner, GNQ Insilico Inc., has entered a Joint Initiative Agreement and Joint Marketing Attachment with a Fortune 100 global technology company. The two-year, non-exclusive collaboration will jointly market AI-driven drug discovery and precision medicine solutions worldwide, combining GNQ’s proprietary AI platforms with the partner’s consulting, cloud, and quantum computing capabilities.
The report also reiterates a proposed business combination between IB Acquisition and GNQ. IB Acquisition plans to file a Form S-4 registration statement with the SEC, including a joint proxy statement/prospectus that will be sent to its stockholders in connection with the transaction.
IB Acquisition Corp. entered into a Business Combination Agreement to acquire GNQ Insilico Inc. by way of a statutory plan of arrangement under Canadian law. The Arrangement Consideration is stated as $500,000,000 plus any Revenue or Share Price Earnouts, with exchange mechanics tying issuance to a Company Exchange Ratio.
The transaction is subject to customary closing conditions including SPAC stockholder approval, court orders in Ontario, regulatory approvals, effectiveness of a Form S-4 registration statement, Nasdaq/NYSE listing approval, minimum net tangible assets of $5,000,001 at closing after redemptions and a possible PIPE, and other conditions. A $10,000,000 break-up fee applies for certain fraudulent or willful breaches. A concurrent Bridge Financing of up to $2,000,000 was arranged, with an initial $250,000 secured convertible note and five-year warrants.